Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $6.2752W HIGH $27.40
Volume
18.85 K
Value Traded
728.38 K
Short % Float
3.41%
+2.56%Week
-28.28%1 Month
-24.92%3 Month
-25.62%6 Month
-95.02%5 Year
-99.32%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
86.18 M
EPS (TTM)
-4.71
P/E Ratio
-
Ent. Value
32.72 M
Total Shares
8.97 M
Float Shares
7.03 M
Insiders
21.59%
Institutions
60.80%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
PMN Catalyst Timeline
Dated clinical, regulatory and corporate events for ProMIS Neurosciences Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for ProMIS Neurosciences Inc.
445Total events
13Upcoming
38Tier-1 (high impact)
2017 to 2027Coverage
Upcoming catalysts 2
Event history 50
◆Oral PresentationPMN310Presentation
Webinar to discuss 6-month blinded interim data from PRECISE-AD
Alzheimer's diseasesource ↗
▲Interim AnalysisPMN310Trial
Positive blinded six-month interim safety and biomarker results from PRECISE-AD
early Alzheimer's diseasesource ↗
▲Enrollment CompletePMN310Trial
PRECISE-AD Phase 1b trial enrollment completed
Alzheimer's diseasesource ↗
▲Enrollment CompletePMN310Trial
Enrollment completed for PRECISE-AD Phase 1b trial
Alzheimer's diseasesource ↗
▲Poster PresentationPMN310Presentation
Poster presentation at AAIC 2026 showing first human evidence of amyloid-beta oligomer target engagement by PMN310
Alzheimer's diseasesource ↗
◆Interim AnalysisPMN310Trial
Blinded 6-month interim data from PRECISE-AD Phase 1b trial reported
early Alzheimer's diseasesource ↗
◆Interim AnalysisPMN310Trial
Blinded 6-month interim analysis of PRECISE-AD trial
Alzheimer's diseasesource ↗
◆Topline ReadoutPMN310Clinical Data
Planned data readout from PRECISE-AD trial
Alzheimer's diseasesource ↗
◆Poster PresentationPresentation
Poster presentation on alpha-synuclein vaccine for Parkinson's at AD/PD 2026
Parkinson's diseasesource ↗
◆Oral PresentationPresentation
ProMIS Neurosciences to participate in fireside chat at Guggenheim Emerging Outlook: Biotech Summit 2026
◆Interim AnalysisPMN310Trial
Six-month interim results expected in 1H 2026
Alzheimer's diseasesource ↗
▲Enrollment CompletePMN310Trial
Enrollment completed with 144 participants
Alzheimer's diseasesource ↗
▲Enrollment CompletePMN310Trial
Enrollment completed with 144 patients in PRECISE-AD Phase 1b trial
Alzheimer's diseasesource ↗
▲PublicationPMN310Presentation
Publication in Alzheimer's & Dementia: Translational Research & Clinical Interventions on selective targeting of toxic oligomers
Alzheimer's diseasesource ↗
▲PublicationPresentation
Publication in Alzheimer's & Dementia journal on plasma pTau as predictive endpoint
Alzheimer's diseasesource ↗
▲Enrollment CompletePMN310Trial
PRECISE-AD completed enrollment with 144 subjects
early Alzheimer's diseasesource ↗
▲Enrollment UpdatePMN310Trial
Phase 1b trial over 85% enrolled; Cohorts 1 and 2 fully enrolled
Alzheimer's diseasesource ↗
◆Oral PresentationPresentation
ProMIS Neurosciences to participate in fireside chat at Guggenheim 2nd Annual Healthcare Innovation Conference
◆Oral PresentationPresentation
H.C. Wainwright 27th Annual Global Investment Conference presentation
▲DSMB ReviewPMN310Trial
DSMB recommends proceeding to final dose escalation cohort
Alzheimer's diseasesource ↗
▲First Patient DosedPMN310Trial
Enrollment and dosing underway for Cohort 3
Alzheimer's diseasesource ↗
▲Enrollment MilestonePMN310Trial
PRECISE-AD Phase 1b trial enrollment surpasses 50% of planned 128 patients
Alzheimer's diseasesource ↗
●Oral PresentationPresentation
Oral presentation on protein-misfolding epitope identification at AAIC 2025
Neurodegenerative diseasessource ↗
●Poster PresentationPresentation
Poster on PRECISE-AD trial design at AAIC 2025
Alzheimer's Diseasesource ↗
▲Fast Track DesignationPMN310Designation
FDA granted Fast Track designation for PMN310
Alzheimer's Diseasesource ↗
▲DSMB ReviewPMN310Trial
DSMB recommended proceeding to second dose level in PRECISE-AD trial
Alzheimer's Diseasesource ↗
▲Enrollment UpdatePMN310Trial
Over 50% of planned 128 patients enrolled in PRECISE-AD
Alzheimer's Diseasesource ↗
●Poster PresentationPresentation
Poster on leveraging biomarkers to optimize early phase drug development in AD at AAIC 2025
Alzheimer's Diseasesource ↗
▼Equity OfferingCorporate
Raised $0.8 million in registered direct offering with pre-funded warrants
▲Fast Track DesignationPMN310Designation
FDA granted Fast Track designation for PMN310 in Alzheimer's disease
Alzheimer's diseasesource ↗
▲Fast Track DesignationPMN310Designation
PMN310 granted Fast Track designation by FDA
Alzheimer's diseasesource ↗
Past FDA Catalysts and PDUFA Decisions
How PMN actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-09-30 | PMN310 | Phase 1b topline data readout | Phase 1b |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
D32 / 100
Pipeline Score
$5M
Pipeline Value
Richly Valued
Valuation Signal
1
Drugs Scored
0.1x
rNPV / MCap
Top 64%
Micro Cap(rank 423 of 660)
Percentile Rank
ProMIS Neurosciences Inc. faces pipeline headwinds (32/100), with $106M risk-adjusted pipeline value, led by PMN310 in Healthy Participants (Phase 1).
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| PMN310 Small moleculeNCT06750432 | Alzheimer Disease, Early Onset | Phase 1 | ACTIVE NOT_RECRUITING | 144 | Dec 1, 2026 |
Clinical Trial Results
Readouts, endpoints and source filings for every PMN program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Kaplan JohanneOfficer (Chief Development Officer) | Buy | 2,280 6,221 held | $13.30 | 08/05/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in PMN
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| Deep Track Capital, LP | 0.2 % | 11.00 M | 835.65 K |
PMN Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How PMN ranks across every disease it competes in
Competitive Position is a premium feature
See how PMN ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialPMN News
PMN▲ +5%today
ProMIS Neurosciences Appoints Seasoned Alzheimer’s and Neuroscience Executive Ivana Rubino, Ph.D., as Chief Commercial Officer
ProMIS Neurosciences has appointed Ivana Rubino, Ph.D., as Chief Commercial Officer, effective October 5, 2026. Dr. Rubino brings over 15 years of experience in Alzheimer's clinical development and commercialization from her previous roles at Biogen and Roche. Her leadership is expected to strengthen ProMIS's strategy as the company approaches key clinical data for its lead candidate, PMN310, in early 2027.
Read more →PMNUpcoming Conferences and Events in October
ProMIS Neurosciences Inc. announced its participation in several upcoming conferences in October 2026, including the H.C. Wainwright Biotech On Tap and the Lausanne XIII Workshop. CEO Neil Warma will represent the company at these events, focusing on discussions related to neurodegenerative diseases. The company aims to foster dialogue and collaboration in the field.
Read more →PMNProMIS Neurosciences to Participate in Upcoming Conferences and Events in September
ProMIS Neurosciences Inc. will participate in several key conferences in September 2026, including the Cantor Global Healthcare Conference and the H.C. Wainwright Annual Global Investment Conference. The company's leadership will discuss its EpiSelect™ platform and the ongoing PRECISE-AD Phase 1b trial for early Alzheimer's disease. Interim data from the trial was reported in July 2026, with further results expected in early 2027.
Read more →PMNProMIS Neurosciences Announces Second Quarter 2026 Financial Results and Provides Corporate Highlights
ProMIS Neurosciences reported positive interim results from its Phase 1b trial of PMN310 for early Alzheimer's disease, showing no cases of ARIA-E among participants. The trial demonstrated early declines in key biomarkers, reinforcing the potential of PMN310. The company ended Q2 2026 with $53.4 million in cash, funding operations through 2027.
Read more →PMNProMIS Neurosciences to Report Second Quarter 2026 Financial Results and Business Update on August 13, 2026
ProMIS Neurosciences Inc. will report its second quarter financial results and provide a business update on August 13, 2026. The company will host a conference call and webcast at 4:30 p.m. ET on the same day. ProMIS focuses on developing antibody therapeutics for neurodegenerative diseases using its proprietary EpiSelect™ technology.
Read more →PMN▲ +23.9%on this news
ProMIS Neurosciences Reports Positive Blinded Six-Month Interim Safety and Biomarker Data for PMN310 in the PRECISE-AD Phase 1b Alzheimer’s Disease Trial
ProMIS Neurosciences announced positive interim results from the PRECISE-AD Phase 1b trial of PMN310, showing no ARIA-E cases and favorable safety across genotypes. Early biomarker movements indicate potential target engagement. The trial remains ongoing, with topline results expected in Q1 2027, which could further validate the drug's efficacy.
Read more →PMN▲ +23.9%on this newsshared move
ProMIS Neurosciences to Host Webinar to Discuss Upcoming 6-Month Blinded Interim Data from PRECISE-AD Phase 1b Trial of PMN310 in Alzheimer’s Disease
ProMIS Neurosciences will host a webinar on July 28, 2026, to discuss six-month interim data from the PRECISE-AD Phase 1b trial of PMN310 in Alzheimer's disease. Key Opinion Leaders will join the company's leadership to analyze safety data and biomarker trends. PMN310 targets toxic amyloid-beta oligomers and has received FDA Fast Track Designation.
Read more →PMN▲ +6.7%on this news· ran to +19% by day 3
ProMIS Neurosciences Reports First Human Evidence of Amyloid-Beta Oligomer Target Engagement by PMN310 at AAIC 2026
ProMIS Neurosciences has reported promising results from its Phase 1a trial of PMN310, showing a dose-dependent reduction of amyloid-beta oligomers in healthy volunteers. This marks a significant milestone in Alzheimer's treatment, as it provides quantitative evidence of target engagement. The company plans to present six-month interim data from its ongoing Phase 1b trial soon.
Read more →PMNProMIS Neurosciences to Participate in Upcoming Conferences in June
ProMIS Neurosciences Inc. will participate in several conferences in June 2026, including the Jefferies Global Healthcare Conference and the Oppenheimer CNS Summit. CEO Neil Warma will present the company's EpiSelect™ platform and its lead Alzheimer's candidate, PMN310. The company expects to report interim data from its Phase 1b trial in early Q3 2026.
Read more →PMNProMIS Neurosciences Announces First Quarter 2026 Financial Results and Provides Corporate Highlights
ProMIS Neurosciences reported its Q1 2026 financial results, highlighting a successful PIPE financing of up to $175 million to fund ongoing operations through 2027. The PRECISE-AD Phase 1b clinical trial for PMN310 is fully enrolled, with an interim analysis expected in early Q3 2026. The company aims to provide insights into PMN310's safety and efficacy in treating Alzheimer's disease.
Read more →PMNTargeting underlying causes of neurodegenerative diseases | 2026 Bloom Burton & Co. Healthcare Investor Conference
Neil K. Warma, CEO of ProMIS Neurosciences, presented at the 2026 Bloom Burton & Co. Healthcare Investor Conference. The focus of the presentation was on addressing the underlying causes of neurodegenerative diseases, showcasing the company's commitment to innovative solutions in this critical area of healthcare.
Read more →PMN▼ -9.1%on this news· ran to -26% by day 3
ProMIS Neurosciences Announces Full Year 2025 Financial Results and Provides Corporate Highlights
ProMIS Neurosciences announced its financial results for 2025, highlighting the completion of enrollment in the PRECISE-AD Phase 1b trial for Alzheimer's disease with 144 patients. The company reported a favorable safety profile for its lead candidate PMN310, which has been granted Fast Track Designation by the FDA. A transformational financing of up to $175 million was closed to support ongoing development efforts.
Read more →PMN▼ -13%on this news
ProMIS Neurosciences to Present Data on ALS & Parkinsons Disease Programs at Alzheimer’s Disease/Parkinson’s Disease 2026 International Conference (AD/PD™)
ProMIS Neurosciences announced that it will present two posters at the AD/PD 2026 conference, showcasing research on therapies targeting misfolded proteins in neurodegenerative diseases. The presentations highlight ongoing work on a vaccine against TDP-43 proteinopathies and an antibody response for toxic alpha-synuclein species. CEO Neil Warma emphasized the importance of this opportunity to advance their candidates' therapeutic approaches for ALS and Parkinson's diseases. The conference will be held in Copenhagen from March 17-21, 2026.
Read more →PMN▼ -16.3%on this news
ProMIS Neurosciences to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
ProMIS Neurosciences will participate in the Guggenheim Emerging Outlook: Biotech Summit 2026, featuring a fireside chat and investor meetings. The company is focused on developing therapies for Alzheimer's disease, with its lead candidate PMN310 showing promise in clinical trials. The PRECISE-AD trial aims to evaluate PMN310's safety and efficacy in patients with mild cognitive impairment due to Alzheimer's.
Read more →PMN▲ +18%on this news
ProMIS Neurosciences Announces Up to $175 Million Private Placement Financing
ProMIS Neurosciences has announced a private placement financing of up to $175 million to support its Phase 1b Alzheimer's disease study and other clinical milestones. The financing is expected to close on February 3, 2026, and will extend the company's cash runway into 2028. The investment is co-led by Janus Henderson and Ally Bridge Group, with participation from various institutional investors.
Read more →PMN▼ -5.6%on this news
ProMIS Neurosciences Exceeds Target Enrollment in PRECISE-AD Phase 1b Clinical Trial of PMN310 in Alzheimer’s Disease
ProMIS Neurosciences has completed enrollment of 144 patients in its PRECISE-AD Phase 1b clinical trial for PMN310, an antibody aimed at treating Alzheimer's disease. The trial seeks to assess the treatment's safety and efficacy over a 12-month period. With a favorable safety profile and no serious adverse events reported, the company anticipates significant data insights from a blinded interim analysis in Q2 2026 and final results in Q4 2026. Strong enthusiasm from patients and physicians reflects the potential value PMN310 may bring to Alzheimer's therapy.
Read more →PMN▲ +12%on this news
ProMIS Neurosciences Announces New Peer-Reviewed Publication Highlighting Selective Targeting of Toxic Oligomers for Potential Clinical Benefit and Reduced ARIA Risk
ProMIS Neurosciences announced a new publication in a peer-reviewed journal demonstrating that its antibody candidate PMN310 selectively targets toxic oligomers related to Alzheimer's disease. The study indicates that PMN310 may improve clinical outcomes by preserving binding to relevant toxic Aβ species and avoiding off-target binding to non-pathogenic forms. With a potential reduction in amyloid-related imaging abnormalities (ARIA), the ongoing PRECISE-AD trial aims to further evaluate PMN310's efficacy and safety, with preliminary results expected in Q2 2026.
Read more →PMNProMIS Neurosciences Announces New Peer-Reviewed Publication Showing Plasma pTau as a Predictive Early Endpoint in Alzheimer’s trials, Supporting its Ongoing Phase 1b PRECISE-AD trial with PMN310
ProMIS Neurosciences announced a peer-reviewed publication validating plasma pTau as a predictive endpoint in Alzheimer's trials. The analysis indicates that plasma pTau can serve as a primary endpoint in early-stage clinical trials, supporting the ongoing Phase 1b PRECISE-AD trial of PMN310. The company anticipates a Q2 2026 interim readout, which may provide early insights into PMN310's efficacy.
Read more →PMNProMIS Neurosciences to Participate in the 8th Annual Evercore Healthcare Conference
ProMIS Neurosciences will participate in the 8th Annual Evercore Healthcare Conference, where CEO Neil Warma will engage in a fireside chat and investor meetings. The company is focused on developing therapies for Alzheimer's disease, with its lead candidate PMN310 currently in a Phase 1b clinical trial. PMN310 has received Fast Track designation from the FDA, highlighting its potential in treating Alzheimer's.
Read more →PMN▼ -22.4%on this news· ran to -36% by day 3
ProMIS Neurosciences Announces Reverse Stock Split
ProMIS Neurosciences Inc. has announced a one-for-twenty-five reverse stock split of its common shares, effective November 28, 2025. The decision aims to address compliance with Nasdaq's minimum bid price requirements after receiving a deficiency notice. The reverse split will reduce the total number of outstanding shares significantly, while adjustments will also be made to equity incentive plans and existing warrants. ProMIS believes that this move could increase its stock price and help maintain its Nasdaq listing.
Read more →About ProMIS Neurosciences Inc.
HeadquartersSUITE 200, 1920 YONGE STREET, TORONTO, A6, M4S 3E2
BIOPHARMAWATCH ELITE PLUS
Trade the next PMN catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime